Redox-Active Quinone Therapeutics for Mitochondrial Energy Biomarker Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for mitochondrial disorders such as Friedreich's ataxia, Leber's Hereditary Optic Neuropathy, MELAS, and Kearns-Sayre Syndrome are inadequate, with few effective options available to manage the severe symptoms associated with these diseases.
Innovation Solution
Development of compounds, including specific quinone derivatives, to modulate energy biomarkers like ATP, coenzyme Q, and lactate levels, which are administered to treat or suppress mitochondrial disorders by normalizing or enhancing these biomarkers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for mitochondrial disorders are used, then some symptom management is provided, but the treatments are inadequate and fail to effectively normalize energy biomarkers
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific chemical structures ( quinone derivatives with particular substituent patterns) that can modulate energy biomarkers. The invention changes the chemical parameters of the treatment agents to achieve effective normalization of ATP, coenzyme Q, and lactate levels, thereby resolving the inadequacy of current treatments.
2Use of energy by moving object
If redox-active compounds are administered to modulate energy biomarkers, then energy production is improved, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent applies universality by designing redox-active compounds that can simultaneously modulate multiple energy biomarkers (ATP, coenzyme Q, lactate) through a single treatment mechanism. This multi-functional approach allows one compound to address multiple aspects of mitochondrial dysfunction, thereby improving energy production without proportionally increasing treatment complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively modulate energy biomarkers, potentially improving symptoms and quality of life for patients with mitochondrial disorders by normalizing or enhancing energy production within cells.
Implementation Method 1
Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
Data Source
AI summary
Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), or Kearns-Sayre Syndrome (KSS) are disclosed, as well as compounds useful in the methods of the invention, such as alpha-tocopherol quinone. Methods and compounds useful in treating other disorders are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.